Pharmacokinetic and Pharmacodynamic Interactions in Polypharmacy Patients

Abstract

Polypharmacy, commonly defined as the concurrent use of multiple medications by a single patient, has become increasingly prevalent due to the rising burden of chronic diseases, aging populations, and advances in medical treatment. While polypharmacy is often necessary for managing complex health conditions, it significantly increases the risk of drug-drug interactions, adverse drug reactions, therapeutic failure, and medication-related complications. Among these concerns, pharmacokinetic and pharmacodynamic interactions play a crucial role in influencing drug efficacy, safety, and overall clinical outcomes. Pharmacokinetic interactions occur when one drug alters the absorption, distribution, metabolism, or excretion of another drug, leading to changes in drug concentration within the body. These interactions frequently involve metabolic enzymes, particularly the cytochrome P450 system, as well as drug transporters and renal elimination pathways. In contrast, pharmacodynamic interactions involve modifications in the pharmacological effects of drugs at their target sites without necessarily altering drug concentrations. Such interactions may result in synergistic, additive, or antagonistic effects, potentially increasing toxicity or reducing therapeutic effectiveness.